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Idiopathic pulmonary fibrosis (IPF) is the most common and severe form of idiopathic inter-
stitial pneumonia. Despite its clinical relevance, few studies have examined the epidemiol-
ogy of IPF and temporal variation in disease incidence and prevalence. Aim of the study
was to investigate the prevalence, incidence and trends of IPF in Lombardy, a region with
nearly 10 million inhabitants, during 2005–2010.
Methods
For the identification of IPF patients, we used healthcare administrative databases of Lombardy
Healthcare System and adopted three algorithms: generic, broad and narrow case definition
(GCD, BCD, NCD). IPF cases were identified according to diagnoses reported in inpatient and
outpatient claims occurred during 2000–2010.We estimated age- and sex-adjusted annual
prevalence and incidence rates from 2005 to 2010, thus allowing for a 5-year washout period.
Results
The mean annual incidence rate was estimated at 2.3 and 5.3 per 100,000 person-years
using NCD and GCD, respectively. IPF incidence was higher among males, and increased
with age. Trend remained stable over the years. The estimated annual prevalence rate was
35.5, 22.4, and 12.6 per 100,000 person-years using GCD, BCD and NCD, respectively,
and increased with age. Moreover, we observed a positive trend over the years. Using BCD
and NCD, prevalence was higher among males.
Conclusions
The results of this study, which is one of the largest population-based survey ever con-
ducted according to strict criteria, indicated that prevalence of IPF increased across the
years while incidence remained stable, thus suggesting that survival with IPF has improved.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is the most common and severe form of idiopathic intersti-
tial pneumonia [1]. It is a progressive disease with a variable clinical course and is associated
with extremely poor prognosis [2–4]. IPF is characterized by a short survival from diagnosis
(3–5 years) and a high fatality rate [5]. Respiratory failure is the most common cause of death;
however, other causes of death, such heart failure, bronchogenic carcinoma, ischemic heart dis-
ease, infection and pulmonary embolism, are frequently concurrent [6,7]. The disease patho-
genesis is not fully understood; however, abnormal wound healing processes and molecular
alterations involved in aging and inflammatory related processes appear to be involved [8,9].
One of the major challenges in epidemiologic studies of such a rare disease has been the dif-
ficulty of recruiting a sufficient number of patients [10]. Few large-scale studies have specifi-
cally focused on epidemiological investigations [9, 11–17]. and the true incidence and
prevalence of IPF are not well established. Difficulties encountered in establishing the epidemi-
ology of IPF may also be due to the lack of uniform definition of IPF in older studies and differ-
ences in diagnostic criteria, study population and design [18,19]. Thus, incidence and
prevalence of IPF vary across the studies. Recent studies indicated that the incidence and mor-
tality of IPF appear to be on the rise [12,18,20,21]; however, data on incidence trends are not
always in agreement [22].
Epidemiology of IPF in Italy has been poorly investigated. In two studies, the prevalence
of IPF has been evaluated analysing data collected in the Italian Registry of Diffuse Infiltra-
tive Pulmonary Diseases, a multicentre prospective registry established in 1998 [23,24].
However, only the percentage of IPF diagnosis among patients affected by interstitial lung
disease (ILD) was evaluated. Moreover, this registry was created using data obtained from
those centres that voluntarily accepted to adhere to the project and, therefore, from those
physicians who spontaneously provided information on number and clinical characteristics
of patients with ILDs. It is likely that the use of this registry might have resulted in an under-
estimation of IPF cases.
In a recent study carried out in the Lazio region (which has about 6 million inhabitants), the
epidemiology of IPF was investigated using hospital admissions and mortality databases of the
regional health system [13]. The annual incidence and prevalence in this large Central-South-
ern Italian region were estimated at 7.5 and 25.6 per 100,000 person-years, respectively; how-
ever Italian trends in incidence and prevalence of IPF are unknown.
The aim of this study was to evaluate the epidemiology of IPF in Lombardy—the most pop-
ulous region of Italy—between 2005 and 2010, by analysing the health care administrative
databases.
Materials and Methods
To investigate the epidemiological characteristics of IPF in Lombardy, a region with nearly 10
million inhabitants (accounting for 16.3% of the Italian population), we performed an observa-
tional retrospective analysis of healthcare administrative databases of the Health Regional
System.
Since the Italian Health Care System provides universal coverage, each region is responsible
for collecting and organizing data on health care services provided to patients; moreover, each
region is charged with storing all such information in databases for administrative purposes. In
order to facilitate the use of these databases for scientific purposes, since 2000 in Lombardy all
data have been inserted in a new data warehouse, named DENALI. DENALI is endowed with a
probabilistic record linkage capable of ameliorating the match of anonymized data of different
datasets belonging to the same individual [25–27].
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For each resident in Lombardy, DENALI contains the following data: demographic charac-
teristics and vital status; hospitalization data, including up to six discharge diagnoses encoded
according to the International Classification of Diseases, ninth Revision, Clinical Modification,
2002 edition (ICD-9-CM) and up to six procedures; description of each outpatient visit, with
the indication of diagnoses (encoded according to ICD-9-CM) or procedures performed dur-
ing that visit.
For our analysis, we first applied a case definition that we called “generic case definition”
(GCD) and that identified as IPF cases all individuals with at least one hospitalization with diag-
nosis of IPF or at least one outpatient visit with diagnosis of IPF (ICD-9-CM code 516.3) during
the period from 1st January 2000 to 31st December 2010. For the identification of cases as inci-
dent or prevalent through claim analysis, the date of the first event (index event) of each patient
was used as a proxy for the timing of disease onset. In addition to GDC, we used the two case def-
initions suggested by Raghu et al. [28], namely the “broad case definition” (BCD) and the “nar-
row case definition” (NCD), with some adjustments in order to adapt them to our context. In
detail, for each subject satisfying GCD we extracted fromDENALI all claims occurred before or
after the index event. We then applied the BCD: we defined IPF cases those patients that satisfied
the GCD and had no claims (inpatient or outpatient) with a diagnosis code for any other type of
ILDs (Table 1) on or after the date of the last claim with IPF diagnosis. Finally, we applied the
NCD: we defined IPF cases those patients that satisfied the BCD and had one or more claim with
a procedure code for surgical lung biopsy, transbronchial lung biopsy or computed tomography
of the thorax (Table 1), on or before the date of the last claim with a diagnosis code for IPF.
Since DENALI doesn’t include information about health services provided prior to 2000,
and the median survival of patients is 3–5 years after the onset of IPF [1,6], the use of DENALI




General Subjects with at least one hospital admission or outpatient visit with IPF diagnosis (ICD-
9-CM code 516.3)
Broad Subjects with:
■ at least one hospital admission or outpatient visit with IPF diagnosis (ICD-9-CM code
516.3)
■ no hospital admission or outpatient visit with ILDs diagnosis (ICD-9-CM codes 135,
237.7, 272.7, 277.3, 277.8, 446.21, 446.4, 495, 500, 501, 502, 503, 504, 505, 506.4,
508.1, 508.8, 515, 516.0, 516.1, 516.2, 516.8, 516.9, 517.2, 517.8, 518.3, 555, 710.0,
710.1, 710.2, 710.3, 710.4, 714.81, 720.0, 759.5) on or after date of last IPF diagnosis
(ICD-9-CM code 516.3)
Narrow Subjects with:
■ at least one hospital admission or outpatient visit with IPF diagnosis (ICD-9-CM code
516.3)
■ no hospital admission or outpatient visit with ILDs diagnosis (ICD-9-CM codes 135,
237.7, 272.7, 277.3, 277.8, 446.21, 446.4, 495, 500, 501, 502, 503, 504, 505, 506.4,
508.1, 508.8, 515, 516.0, 516.1, 516.2, 516.8, 516.9, 517.2, 517.8, 518.3, 555, 710.0,
710.1, 710.2, 710.3, 710.4, 714.81, 720.0, 759.5) on or after date of last IPF diagnosis
(ICD-9-CM code 516.3)
■ at least one surgical lung biopsy (ICD-9-CM codes 33.28), transbronchial lung biopsy
(ICD-9-CM codes 33.27) or computed tomography of the thorax (ICD-9-CM codes
87.41) performed during an hospitalization or outpatient visit, on or before date of last
IPF diagnosis (ICD-9-CM code 516.3)
IPF, idiopathic pulmonary fibrosis; ICD-9-CM, international classification of diseases, 9th revision; ILD,
interstitial lung disease.
doi:10.1371/journal.pone.0147072.t001
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data from 2000 to 2004 might result in an underestimation of the number of prevalent cases
and, at the same time, an overestimation of the number of incident cases until 2004. To ensure
that the index event is a good proxy for the onset of IPF, information about health system
accesses should be documented for at least five years before the onset itself. For these reasons,
we only analysed the period 2005–2010, and incident IPF patients were identified among
patients who had been covered by the Lombardy health care system for at least 5 years before
the index event (washout period).
Using the three case definitions (GCD, BCD, NCD), we assessed the overall prevalence and
incidence rates of IPF as well as prevalence and incidence rates stratified by gender and age
(<55, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, and85 years). Finally, we evaluated tempo-
ral trends by computing yearly prevalence and incidence rates standardized by age and gender,
using the population living in Lombardy at January 1st 2010 as reference [29].
We assumed a Poisson distribution of the rates and computed 95% confidence interval
(95% CI) based on Normal approximation [30]. In order to test for age-related and temporal
linear trends, for each case definition we computed the count of expected incident (or preva-
lent) cases in the reference population stratified by gender, age classes and calendar year, and
then we used these counts as dependent variable in a Poisson regression model with the follow-
ing structure:
log EðYiÞ ¼ logNi þ b0 þ b1IMales;i þ b2Agei þ b3Yeari ð1Þ
where Yi is the expected count in the i-th stratum; Ni is person-years at risk in the i-th stratum;
IMales,i is an indicator variable that assumes value 1 when the gender is male in the i-th stratum;
Agei is the age class of the i-th stratum and Yeari is the calendar year of the i-th stratum. A sig-
nificant Wald’s test for β2 and β3 indicated respectively an age-related and a temporal linear
trend in the dependent variable.
For all statistical tests, a pre-specified two-sided α of 0.05 was regarded as significant.
The analyses were performed using SAS software, version 9.2 (SAS Institute, Cary, NC,
USA) and R, version 3.1.1 (R Project for Statistical Computing, http://www.R-project.org).
Results
Study population
Using the DENALI data warehouse, we found that a total of 11,558 hospital admissions with
diagnosis of IPF and 5,117 outpatient visits with an IPF diagnosis occurred over the years 2000–
2010. Limiting the analysis to 2005–2010, the number of subjects with IPF identified through the
hospital discharge diagnoses alone were 4,872 using the GCD, 3,255 using the BCD, and were
2,094 using the NCD; however, since we also searched for IPF diagnosis in outpatient visits, sam-
ple sizes raised, and a total of 5,441 (+11.7%), 3,573 (+9.8%), and 2,097 (+0.1%) IPF patients
were identified using the GCD, BCD and NCD, respectively (data not shown).
Prevalence
The number of IPF cases identifies as prevalent in Lombardy during 2005–2010 is reported in
Table 2: the results are illustrated according to the three IPF case definitions, and stratified by
gender and age groups. Based on the GCD, BCD and NCD, the number of prevalent cases of
IPF was 5,441 (53.8% of whom were male), 3,573 (male: 57.2%) and 2,097 (male: 56.9%),
respectively. About 70% of patients were aged 65 and older, regardless of the case definition.
Using to the GCD, the estimated average annual prevalence rate (per 100,000 person-years)
was 35.51 (95% CI: 35.02–36.00), with no significant differences between genders (Table 3).
Epidemiology of IPF in Northern Italy
PLOS ONE | DOI:10.1371/journal.pone.0147072 February 3, 2016 4 / 15
The prevalence of diagnosed IPF increased with increasing age, rising from 9.77 for people
aged less than 55 years (95% CI: 9.46–10.08) to 143.71 for people aged 80–84 years (95% CI:
137.89–149.53). However, prevalence dropped to 99.20 (95% CI: 93.66–104.74) for people aged
85 years and older.
Using the BCD, the estimated mean annual prevalence rate (per 100,000 person-years) was
22.39 (95% CI: 21.99–22.78), and was significantly higher in males (23.64; 95% CI: 23.08–
24.20) than females (21.07; 95% CI: 20.52–21.62). The age-stratified analyses yielded similar
results to those obtained using the GCD, with the lowest mean annual prevalence being in the
youngest group of age (5.67; 95% CI: 5.44–5.91) and the highest among people aged 80–84
years (97.14; 95% CI: 92.36–101.92); then, mean annual prevalence decreased to 72.72 (95%
CI: 67.98–77.46) for people aged 85 years and older.
Finally, the average annual prevalence rate (per 100,000 person-years) as estimated accord-
ing to the NCD was 12.55 (95% CI: 12.26–12.84). As observed using the BCD, prevalence was
higher in males (13.23; 95% CI: 12.82–13.65) than in females (11.84; 95% CI: 11.43–12.25);
moreover, the age-stratified analyses showed a pattern that was similar to that obtained using
the GCD and BCD.
The trends observed in age classes were confirmed by the Poisson regression models
(Table 4) for all case definitions: the estimated β for age class was always significantly positive.
The analysis of the temporal trend revealed that the annual standardized prevalence rates
increased from 2005 to 2008, and seemed to stabilize thereafter, regardless of the case definition
(Fig 1). However, the stabilization was more evident when the analysis was performed using
the GCD. The Poisson model reported in Table 4, detected an overall growing trend related to
calendar year.
Incidence
From 2005 to 2010, a total of 2,951, 2,093 and 1,309 new cases of IPF were registered in Lom-
bardy using the GCD, BCD and NCD, respectively. Results are illustrated in Table 2. About
Table 2. Demographic characteristics of prevalent and incident cases of IPF from 2005 to 2010 in Lombardy by case definition.
Prevalent cases Incident cases
GCD BCD NCD GCD BCD NCD
N (%) N (%) N (%) N (%) N (%) N (%)
Total 5,441 3,573 2,097 2,951 2,093 1,309
Gender
Male 2,929 (53.83) 2,042 (57.15) 1,193 (56.89) 1,674 (56.73) 1,252 (59.82) 772 (58.98)
Female 2,512 (46.17) 1,531 (42.85) 904 (43.11) 1,277 (43.27) 841 (40.18) 537 (41.02)
Age group (years)
<55 860 (15.81) 515 (14.41) 306 (14.59) 361 (12.23) 242 (11.56) 155 (11.84)
55–59 429 (7.88) 259 (7.25) 161 (7.68) 200 (6.78) 132 (6.31) 83 (6.34)
60–64 530 (9.74) 338 (9.46) 217 (10.35) 293 (9.93) 201 (9.60) 142 (10.85)
65–69 737 (13.55) 482 (13.49) 302 (14.40) 400 (13.55) 288 (13.76) 185 (14.13)
70–74 870 (15.99) 578 (16.18) 348 (16.60) 500 (16.94) 346 (16.53) 216 (16.50)
75–79 929 (17.07) 607 (16.99) 354 (16.88) 544 (18.43) 382 (18.25) 238 (18.18)
80–84 720 (13.23) 516 (14.44) 278 (13.26) 416 (14.10) 315 (15.05) 186 (14.21)
85+ 366 (6.73) 278 (7.78) 131 (6.25) 237 (8.03) 187 (8.93) 104 (7.94)
GCD, generic case definition; BCD, broad case definition; NCD, narrow case definition.
doi:10.1371/journal.pone.0147072.t002
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60% of new cases occurred in males, regardless of the case definition. The majority of incident
cases (63% of the total) occurred in subjects aged 65 to 84 years. Age distribution of incident
cases did not significantly differ among the three case definitions.
Using the GCD, the estimated annual incidence rate (per 100,000 person-years) was 5.25
(95% CI: 5.06–5.44), and was significantly higher among males (6.18; 95% CI: 5.88–6.48) than
females (4.37; 95% CI: 4.13–4.61) (Table 5).
Similarly to prevalence rate, the incidence rate increased with increasing age, with the lowest
value being in the youngest age group: the rate (per 100,000 persons-years) rose from 0.92
among people aged less than 55 years (CI%: 0.82–1.01) to 25.59 among people aged 80–84
Table 3. Estimates of the mean annual standardized IPF prevalence rates (per 100,000 person-years)
in Lombardy during the period 2005–2010 by gender, age, and case definition.
GCD BCD NCD
Adjusted rates per 100,000 person-years (95% CI)
Overall 35.51 (35.02–36.00) 22.39 (21.99–22.78) 12.55 (12.26–12.84)
Male 35.19 (34.51–35.87) 23.64 (23.08–24.20) 13.23 (12.82–13.65)
Female 35.84 (35.13–36.55) 21.07 (20.52–21.62) 11.84 (11.43–12.25)
Age classes
<55 9.77 (9.46–10.08) 5.67 (5.44–5.91) 3.22 (3.04–3.39)
55–59 45.34 (43.18–47.51) 27.09 (25.42–28.76) 16.98 (15.66–18.30)
60–64 60.45 (57.85–63.05) 35.47 (33.48–37.46) 20.90 (19.37–22.43)
65–69 84.79 (81.66–87.93) 53.94 (51.44–56.44) 32.21 (30.27–34.14)
70–74 106.36 (102.60–110.13) 68.83 (65.80–71.85) 39.47 (37.17–41.76)
75–79 133.37 (128.66–138.08) 84.43 (80.69–88.17) 46.40 (43.62–49.17)
80–84 143.71 (137.89–149.53) 97.14 (92.36–101.92) 51.28 (47.81–54.75)
85+ 99.20 (93.66–104.74) 72.72 (67.98–77.46) 32.54 (29.37–35.71)
Unadjusted rates per 100,000 person-years (95% CI)
Male
<55 10.29 (9.84–10.75) 4.96 (4.65–5.28) 3.51 (3.25–3.79)
55–59 46.65 (43.63–49.83) 23.27 (21.11–25.59) 19.38 (17.45–21.46)
60–64 63.57 (59.91–67.38) 28.87 (26.34–31.57) 25.26 (22.97–27.71)
65–69 84.07 (79.83–88.48) 51.28 (47.79–54.96) 33.47 (30.81–36.29)
70–74 100.67 (95.80–105.72) 69.17 (64.71–73.86) 37.97 (35.00–41.12)
75–79 118.03 (112.37–123.91) 91.82 (85.80–98.15) 42.43 (39.07–46.01)
80–84 108.53 (102.41–114.92) 131.18 (121.95–140.92) 41.88 (38.11–45.92)
85+ 53.87 (49.31–58.75) 158.36 (144.90–172.73) 19.68 (16.96–22.71)
Female
<55 9.28 (8.86–9.71) 6.42 (6.07–6.79) 2.93 (2.70–3.18)
55–59 43.98 (40.99–47.12) 30.75 (28.31–33.35) 14.48 (12.79–16.33)
60–64 57.13 (53.56–60.88) 41.68 (38.74–44.80) 16.26 (14.39–18.32)
65–69 85.60 (81.07–90.31) 56.32 (52.85–59.94) 30.80 (28.10–33.67)
70–74 113.12 (107.40–119.07) 68.53 (64.53–72.72) 41.24 (37.81–44.90)
75–79 154.52 (146.68–162.67) 79.07 (74.45–83.91) 51.86 (47.36–56.67)
80–84 205.43 (193.84–217.53) 77.75 (72.58–83.18) 67.78 (61.19–74.88)
85+ 224.63 (208.54–241.63) 41.77 (37.76–46.09) 68.13 (59.41–77.78)
GCD, generic case definition; BCD, broad case definition; NCD, narrow case definition; 95%CI, 95%
confidence interval.
doi:10.1371/journal.pone.0147072.t003
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years (95% CI: 23.13–28.06), and then decreased to 18.91 (95% CI: 16.50–21.31) for the oldest
population (85+ age group).
Using the BCD, the overall annual incidence rate (100,000 person-years) was 3.74 (95% CI:
3.58–3.90). The rate was significantly higher among males (4.63; 95% CI: 4.37–4.89). The age-
stratified analysis showed a pattern that was similar to that observed using the GCD, although
the point estimates were lower: the lowest incidence rate, estimated for people aged less than 55
years, was 0.62 (95% CI: 0.54–0.69), and the highest rate (which was estimated for people aged
80 to 84 years) was 19.40 (95% CI: 17.26–21.55).
Using the NCD, the mean annual incidence rate (per 100,000 person-years) was estimated
at 2.33 (95% CI: 2.20–2.46), with higher values in males (2.85; 95% CI: 2.65–3.05) than females
(1.84; 95% CI: 1.68–2.00). The age-stratified analysis revealed a pattern that was similar to that
observed using the GCD and BCD: the incidence rate rose from 0.39 among people younger
than 55 years of age (95% CI: 0.33–0.46) to 11.45 among people aged 80–84 years (95% CI:
9.81–13.10), and then dropped for subjects aged 85 years and older.
For all case definitions, Poisson regression models (Table 6) confirmed the significance of
the trends observed for age classes: the estimated β for age class was always significantly
positive.
The analysis of the temporal trend during the period 2005–2010 revealed that, using the
GCD, the estimated annual incidence rates slightly decreased, with a more consistent decline
over the last two years (Fig 2). However, the analysis of temporal trend using the BCD and
NCD revealed that the annual incidence rates were stable during the study period, with the
only exception of the year 2009, when a sudden decrease was observed. The overall Poisson
regression model detected a significant negative trend for all case definition (Table 6). How-
ever, such trend was not confirmed for BCD and NCD when the model excluded 2009 data.
Discussion
In our study we used healthcare administrative databases to evaluate epidemiology of IPF in
Lombardy, which, with nearly 10 million inhabitants in 2013, is the most populous region of
Italy. As highlighted in a recent review [19], the analysis of health care databases is one of the
most common methodologies used to identify cases of IPF. This approach provides informa-
tion from a large population without the expenditure required by the creation of a national reg-
istry; moreover, it is critical for accruing a sufficient sample size for epidemiological studies for
rare diseases such IPF.
Table 4. Results of Poisson regression models on expected prevalence rates in the reference population (population of Lombardy at January 1st
2010).
GCD BCD NCD
β SE p-valuea β SE p-valuea β SE p-valuea
Calendar year 0.0298 0.0040 <0.0001 0.0499 0.0051 <0.0001 0.0580 0.0068 <0.0001
Age class 0.3790 0.0026 <0.0001 0.3942 0.0033 <0.0001 0.3767 0.0044 <0.0001
Gender
Male 0.2543 0.0140 <0.0001 0.1328 0.0177 <0.0001 0.1198 0.0236 <0.0001
Female ref. ref. ref.
GCD, Generic Case Definition; BCD, Broad Case Definition; NCD, Narrow Case Definition; SE, Standard Error.
a Wald’s test.
doi:10.1371/journal.pone.0147072.t004
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In our study, the estimated mean annual incidence rate of IPF varied between 2.3 and 5.3
per 100,000 person-years, and the estimated prevalence rate varied between 12.6 and 35.5 per
100,000 person-years, depending on the case definition used to identify IPF patients.
The comparison between our results and findings from other studies is hampered by the
variety of IPF case definitions and by differences in study population, time period of analysis,
and geographic locations. In the US, two different research groups studied the incidence and
prevalence of IPF by analyzing medical claims databases [28,31]; however, the broad and nar-
row definitions that were used in those studies included slightly different criteria. Raghu et al.
[28] estimated the incidence rate to be 6.8 and 16.3 per 100,000 person-years in the year 2000
using their narrow and broad definition, respectively; in the study of Fernandez-Perez et al.
[31], which focused on the epidemiology of IPF during the period 1997–2005, the estimated
incidence rate was 8.8 per 100,000 person-years based on their narrow definition, and was 17.4
Fig 1. Trend in age-sex standardized annual prevalence rates (per 100,000 person-years) of IPF in
Lombardy during 2005–2010, by case definition. (A) General case definition. (B) Broad case definition. (C)
Narrow case definition. Grey bands indicate 95% confidence intervals.
doi:10.1371/journal.pone.0147072.g001
Epidemiology of IPF in Northern Italy
PLOS ONE | DOI:10.1371/journal.pone.0147072 February 3, 2016 8 / 15
per 100,000 person-years based on their broad definition. The overall prevalence of IPF esti-
mated by Raghu et al. [28] was 14.0 and 42.7 per 100,000 person-years using their narrow and
broad definition, respectively, while the prevalence estimated by Fernandez-Perez et al. [31]
was 27.9 and 63.0 per 100,000 person-years by their narrow and broad definition criteria,
respectively. It should be noted that only residents aged 50 years and older were evaluated in
the Fernandez-Perez et al. study [31].
In Japan, only one study has been conducted to investigate the epidemiology of IPF [17],
and the results suggested that the estimated prevalence and incidence in 2008 appear to be
much lower (10.0 and 2.2 per 100,000 person-years, respectively) than those observed in the
US population.
Table 5. Estimates of the mean annual standardized IPF incidence rates (per 100,000 person-years) in
Lombardy during the period 2005–2010 by gender, age, and case definition.
GCD BCD NCD
Adjusted rates per 100,000 person-years (95% CI)
Overall 5.25 (5.06–5.44) 3.74 (3.58–3.90) 2.33 (2.20–2.46)
Male 6.18 (5.88–6.48) 4.63 (4.37–4.89) 2.85 (2.65–3.05)
Female 4.37 (4.13–4.61) 2.88 (2.69–3.08) 1.84 (1.68–2.00)
Age classes
<55 0.92 (0.82–1.01) 0.62 (0.54–0.69) 0.39 (0.33–0.46)
55–59 5.36 (4.62–6.10) 3.54 (2.93–4.14) 2.22 (1.75–2.70)
60–64 8.51 (7.54–9.49) 5.84 (5.03–6.65) 4.13 (3.45–4.80)
65–69 12.08 (10.90–13.27) 8.70 (7.70–9.70) 5.59 (4.78–6.39)
70–74 17.40 (15.88–18.93) 12.06 (10.79–13.34) 7.53 (6.52–8.53)
75–79 23.69 (21.70–25.68) 16.68 (15.01–18.36) 10.40 (9.08–11.72)
80–84 25.59 (23.13–28.06) 19.40 (17.26–21.55) 11.45 (9.81–13.10)
85+ 18.91 (16.50–21.31) 14.93 (12.79–17.07) 8.29 (6.69–9.88)
Unadjusted rates per 100,000 person-years (95% CI)
Male
<55 0.98 (0.85–1.13) 0.70 (0.59–0.82) 0.42 (0.34–0.52)
55–59 5.68 (4.64–6.88) 4.15 (3.27–5.20) 2.57 (1.89–3.41)
60–64 10.98 (9.45–12.69) 7.80 (6.52–9.26) 5.46 (4.40–6.71)
65–69 15.81 (13.90–17.91) 11.65 (10.02–13.47) 7.49 (6.20–8.98)
70–74 21.67 (19.20–24.36) 16.33 (14.20–18.68) 9.83 (8.19–11.69)
75–79 33.80 (30.18–37.72) 25.61 (22.48–29.06) 16.05 (13.59–18.82)
80–84 40.98 (35.90–46.58) 31.87 (27.41–36.86) 18.74 (15.36–22.64)
85+ 34.53 (28.41–41.59) 28.00 (22.52–34.42) 14.62 (10.74–19.44)
Female
<55 0.86 (0.73–1.00) 0.53 (0.43–0.65) 0.36 (0.28–0.46)
55–59 5.05 (4.09–6.17) 2.95 (2.23–3.83) 1.90 (1.33–2.62)
60–64 6.19 (5.09–7.46) 3.99 (3.12–5.04) 2.87 (2.14–3.77)
65–69 8.74 (7.41–10.24) 6.05 (4.96–7.32) 3.88 (3.02–4.92)
70–74 13.81 (12.04–15.76) 8.47 (7.10–10.03) 5.59 (4.49–6.87)
75–79 16.37 (14.30–18.64) 10.21 (8.59–12.04) 6.30 (5.05–7.77)
80–84 16.83 (14.47–19.46) 12.30 (10.29–14.57) 7.30 (5.78–9.10)
85+ 13.26 (11.04–15.78) 10.21 (8.28–12.45) 6.00 (4.54–7.77)
GCD, generic case definition; BCD, broad case definition; NCD, narrow case definition; 95%CI, 95%
confidence interval.
doi:10.1371/journal.pone.0147072.t005
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In general, IPF estimates of prevalence and incidence rates appear to be lower in Europe rel-
ative to those reported in the US population [18,20,22]. In particular, studies that investigated
the IPF epidemiology during the first years of the 21st century–which, therefore, are compara-
ble to our study—found that the estimated mean annual incidence rate (per 100,000 person-
years) ranged from 0.9 in Greece [32] to 7.4 in UK [33]; the estimated prevalence rate was only
evaluated in Greece, and was 3.4 [32]. Recently, the study of Agabiti et al. [13] focused on epi-
demiology of IPF in the adult population of a region of Central-Southern Italy using hospital
admission records: findings indicated that the estimated annual incidence rate over the period
2005–2009 varied between 7.5 and 9.3 (per 100,000 person-years), and that the estimated IPF
prevalence in 2009 varied between 25.6 and 31.6 (per 100,000 person-years), depending on the
case definition. These results show a higher incidence and a lower prevalence rate than ours.
These differences might be due to different demographic characteristics of the analysed popu-
lations, or to environmental factors, for example Lazio and Lombardy differ for climate as well
as concentration and sources of environmental pollution, or they might be even due to differ-
ences in the patient management, as each region of Italy has its own Healthcare System that is
to some extent autonomous. However, we can’t rule out that, they might also originate from
differences in study design: first, our estimates refer to the whole population, while those from
Agabiti are related to people aged 18 or older; second, the criteria used in the study of Agabiti
et al. were similar to the GCD criteria used in our study, but did not include outpatient claims;
finally, different washout periods were used to identify IPF cases as incident or prevalent.
Our findings suggested that prevalence and incidence of IPF in Lombardy might be similar
to those estimated in other European countries, and thus lower compared to those observed in
the United States; however, the use of different IPF case definitions and differences in subject
selection criteria might invalidate a direct comparison of findings among countries [18,19].
Our results are consistent with several previous surveys finding that incidence and preva-
lence of IPF are higher among men, and increase with increasing age [11,17,28,31,33–35].
Interestingly, we observed that both prevalence and incidence of IPF significantly decreased in
the oldest age group (aged 85 years and older). A similar pattern of incidence and prevalence
Table 6. Results of Poisson regression models on expected incidence rates in the reference population (population of Lombardy at January 1st
2010).
GCD BCD NCD
β SE p-valuea β SE p-valuea β SE p-valuea
Overall model
Calendar year -0.0683 0.0105 <0.0001 -0.0270 0.0124 0.0298 -0.0310 0.0158 0.0492
Age class 0.4598 0.0069 <0.0001 0.4782 0.0083 <0.0001 0.4628 0.0104 <0.0001
Gender
Male 0.6552 0.0367 <0.0001 0.8026 0.0440 <0.0001 0.7467 0.0556 <0.0001
Female ref. ref. ref.
Model excluding year 2009
Calendar year -0.0560 0.0114 <0.0001 -0.0044 0.0132 0.7411 -0.0004 0.0166 0.9814
Age class 0.4527 0.0074 <0.0001 0.4699 0.0088 <0.0001 0.4531 0.0110 <0.0001
Gender
Male 0.6547 0.0394 <0.0001 0.8147 0.0473 <0.0001 0.7878 0.0594 <0.0001
Female ref. ref. ref.
GCD, Generic Case Definition; BCD, Broad Case Definition; NCD, Narrow Case Definition; SE, Standard Error.
a Wald’s test.
doi:10.1371/journal.pone.0147072.t006
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rates was observed in the study conducted in UK by Gribbin et al. [35], and might be related to
clinical complexities inherent in elderly patients.
In our study, we not only assessed the prevalence and incidence of IPF but also provided
information about temporal trend. To our knowledge, only four studies have focused on this
aspect [11,31,33,35]. Two of these studies investigated temporal trends before 2005 [31,35].
The other two studies indicated that incidence rates remained stable in the UK [33] and the US
[11] since 2005 and that IPF prevalence in the US has increased annually in recent years [10].
Results from our study are in line with such findings: the analysis of temporal trend revealed
that the annual incidence rates estimated using the BCD and NCD were stable in Lombardy
during the study period, while IPF prevalence (per 100,000 person-years) increased from 19.0
in 2005 to 24.7 in 2010 using BCD, and from 10.2 in 2005 to 13.9 in 2010 using NCD (Fig 1).
This increase might be attributable to a gain in survival of patients developing IPF during the
Fig 2. Trend in age-sex standardized annual incidence rates (per 100,000 person-years) of IPF in
Lombardy during 2005–2010 by case definition. (A) General case definition. (B) Broad case definition. (C)
Narrow case definition. Grey bands indicate 95% confidence intervals.
doi:10.1371/journal.pone.0147072.g002
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last years as a result of recent advances in the diagnosis and management of the disease and in
particular of comorbidities [11]. However, it should be noted that we observed a significant
drop in incidence rate during 2009. Such anomaly might be the consequence of a change in leg-
islation establishing administrative and management protocols in Lombardy: indeed, in this
period it was established that some health care services that were previously provided in day-
hospitals would be provided in outpatient settings. The adaptation to the new legislation might
have resulted in a temporary reduction in the number of hospitalizations in 2009, which, how-
ever, ended before the following year. Such adaptation problems may also account for the
results on prevalence trend: the increase in prevalence observed from 2005 to 2007 flattened
between 2008 and 2009; afterwards, prevalence rate continued to increase. In order to assess
the influence of the drop on the overall mean annual rates, we computed rates excluding the
year 2009 and we obtained slightly higher incidence rates: 5.46 (95% CI: 5.24–5.67), 3.91 (95%
CI: 3.73–4.09) and 2.47 (95%CI: 2.33–2.62) respectively for GCD, BCD and NCD; and we esti-
mated minimally lower prevalence rates: 35.18 (95%CI: 34.64–35.72), 22.10 (95%CI: 21.67–
22.52), 12.37 (95%CI: 12.05–12.68). It should be noted that the differences with the estimates
reported in Tables 3 and 5 are not significant because the confidence intervals always overlap.
The same conclusion applies to age or gender stratified rates (results not shown). Therefore, we
can conclude that including 2009 in the analysis does not lead to bias in the estimated rates.
Our study was carried out using health care administrative databases and, therefore, it has
some limitations, as already suggested by Raghu et al [11,28]. First, patients with IPF were iden-
tified based on their access to health care services: as a matter of fact, it was impossible to deter-
mine the exact timing of the onset of IPF and, therefore, the date of the first encounter with the
inpatient or outpatient healthcare system facility coinciding with the first recorded medical
diagnostic claim of IPF was used as a proxy for the timing of disease onset. Second, the accu-
racy of the reported diagnoses in the hospital admissions databases was unknown as we could
not integrate in the study a clinical review of each medical chart or of a representative sample
of them. In the study of Agabiti et al. [13], it was found that a number of revised hospital charts
carrying the ICD9-CM 515 code (post inflammatory pulmonary fibrosis), 516.8 code (other
specified alveolar and parietoalveolar pneumonopathies) and 516.9 code (unspecified alveolar
and parietoalveolar pneumonopathies) were eventually redefined as “IPF confident” cases.
Therefore, some extent of misdiagnosis or misreporting of IPF cases might occur, thus result-
ing in an underestimation of IPF cases [13]. Moreover, the sensitivity of the ICD-9-CM code
516.3 in identifying IPF cases might be low [13], as this code includes some extremely rare con-
ditions such as the alveolar capillary block and Hamman-Rich syndrome [11]; furthermore,
some other ILDs might be wrongly coded as 516.3 without appropriate health examinations.
We partially overcame this latter limitation by recognizing patients using the broad and narrow
case definitions, which consider patients’medical history before and after the presumed IPF
onset and, therefore, exclude those patients for whom such types of miscoding might have
occurred. Nevertheless, as we observed that patients who were likely to be misclassified as hav-
ing IPF received a diagnosis of ILD other than IPF within two years after the presumed onset, a
certain extent of misclassification might have persisted in 2009 and 2010.
From a methodological point of view, we based our case definitions on the most rigorous
available criteria that were suitable for the analysis of the administrative data [11,28]; in addi-
tion, we included outpatient claims. Compared to the study of Agabiti et al. [13], this approach
had the advantage of allowing identification of patients who had never been admitted to hospi-
tal because of IPF (and accounted for about 10% of IPF cases, as observed using the general
and broad case definitions). Furthermore, the identification of IPF cases as prevalent or inci-
dent was based on criteria that were much stricter than those used in the above-mentioned
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studies [11,28]: indeed, we used a longer washout period (5-years) in order to minimize the
probability of misclassification of prevalent as incident IPF case.
Despite the above-mentioned limitations, we believe that health care administrative data-
bases are useful tools to investigate the epidemiology of a rare disease like IPF. This approach
allowed us to select a sample of population that was larger than those evaluated in most of the
published studies. Indeed, this was one of the biggest sample ever considered, together with
studies conducted in UK [33,35]: to date, the largest sample in US was composed of roughly
3.7 million inhabitants [11,28], which accounted for about 37% of the population selected for
our study. Besides, our study investigated for the first time trends in IPF incidence and preva-
lence in an Italian region.
Moreover, thanks to the universal health care coverage and to the DENALI data warehouse,
which traces a complete medical history of each resident in Lombardy by merging data of dif-
ferent datasets belonging to the same individual, we could investigate the prevalence and inci-
dence of IPF in an unselected population, without restrictions related to age [11,13,31],
adherence to some health plan (e.g. Medicare) [11,28], or voluntary recruitment [17,32].
In conclusion, our results on IPF prevalence and incidence are in line with those reported in
other epidemiological studies conducted in Italy and Europe, and incidence and prevalence
trends are in agreement with those reported in European and American studies. The conver-
gence of findings from different epidemiological studies of IPF—some of which were also per-
formed using administrative databases—is a very important achievement, considering all the
challenges that are faced in investigating epidemiology of rare diseases (e.g. diagnostic issues
and difficulties of study design). Future studies are warranted to validate the accuracy of the
diagnostic codes used to identify IPF cases in large databases, as well as to investigate different
target populations, living in areas with different geographical, social and environmental
characteristics.
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